Biotech Values

[DewDiligence]

IMRA reverse-merges with Enliven Therapeutics:

https://www.globenewswire.com/news-release/2022/10/13/2534321/0/en/Enliven-Therapeutics-and-Imara-Announce-Merger-Agreement.html

Upon completion of the merger, which is subject to approval by Imara’s and Enliven’s stockholders, the combined company is expected to operate under the name Enliven Therapeutics, Inc. and trade on the Nasdaq Global Select Market under the ticker symbol ELVN.

…Pre-merger Imara stockholders are expected to own approximately 16% of the combined company and pre-merger Enliven stockholders (including those purchasing Enliven shares in the private financing discussed above) are expected to own approximately 84% of the combined company.

… Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.

The corporate description of ELVN (above) doesn’t say much beyond platitudes.

IMRA became a shell company six months ago (#msg-168556547).